Ocular Cancer Drug Development Pipeline Review, 2018
- Pages: 63
- Published: May 2018
- Report Code: GBIHC036IDB
This report provides an overview of the pipeline landscape for ocular cancer and comprehensive information on the therapeutics under development and key players involved in therapeutic development for retinoblastoma and uveal melanoma. It also features dormant and discontinued products.
Retinoblastoma is an eye cancer that begins in the retina. Symptoms include white color in the center circle of the eye (pupil), eye redness, vision problems, a different color in each iris and eye swelling.
The predisposing factors include age and heredity. There are seven products in active development for this indication and companies operating in this space include Ophthotech and VCN Biosciences.
Uveal melanoma, the most common intraocular tumor, is a disease in which melanocytes, found in the part of the eye called the uvea, become cancerous. Symptoms include dark spot on the iris, glaucoma, eye pain and eye redness.
Uveal melanoma is more common in people who have atypical mole syndrome, dysplastic nevus syndrome, and ocular or oculodermal melanocytosis. There are 35 products in active development for this indication and companies operating in this space include Novartis and Eli Lilly.
Molecular targets acted on by products in development for ocular cancer include tumor antigens, kinases and growth factor receptors.
Scope
– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Companies mentioned
Aeglea BioTherapeutics Inc
APEIRON Biologics AG
Bellicum Pharmaceuticals Inc
Bristol-Myers Squibb Co
Celldex Therapeutics Inc
Cleveland BioLabs Inc
Delcath Systems Inc
Eli Lilly and Co
EyePoint Pharmaceuticals Inc
Iconic Therapeutics Inc
Immunocore Ltd
Innovation Pharmaceuticals Inc
Iovance Biotherapeutics Inc
Novartis AG
Ophthotech Corp
PEP-Therapy SAS
PepVax Inc
Pfizer Inc
Plexxikon Inc
Polaris Pharmaceuticals Inc
Syndax Pharmaceuticals Inc
Tesaro Inc
VCN Biosciences SL
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.